Heart Failure
INVESTED: High-dose influenza vaccine fails to reduce death, CV events in high-risk cohort
Injection of a high-dose influenza vaccine did not affect all-cause death, cardiac or pulmonary hospitalization compared with a lower dose in patients with prior MI or HF hospitalization, according to findings from the INVESTED trial.
Iron supplementation for deficiency in acute HF lowers risk for future hospitalization
Supplementation in iron-deficient patients hospitalized with acute HF reduced subsequent HF hospitalization by approximately 26% compared with placebo, according to findings from the AFFIRM-AHF trial.
Omecamtiv mecarbil lowers CV death/HF events in HFrEF: GALACTIC-HF
Omecamtiv mecarbil, a novel selective cardiac myosin activator, was associated with an 8% reduction in CV death or first HF events in patients with HF with reduced ejection fraction, according to results of the GALACTIC-HF trial.
Empagliflozin shows cardiovascular benefits, slows kidney function decline
For patients with heart failure, empagliflozin led to reduced risk for cardiovascular mortality and heart failure hospitalizations, while slowing kidney function decline regardless of chronic kidney disease status at baseline.
Undiagnosed OSA associated with increased costs, readmission in patients with heart failure
Previously undiagnosed obstructive sleep apnea in patients hospitalized with congestive heart failure was associated with increased costs and readmissions at 3 and 6 months compared with patients without sleep-disordered breathing, researchers reported.
Nighttime BP may be independent predictor of future CVD
Fluctuations in nighttime BP may represent a key predictor of future stroke, CAD and HF, according to a study published in Circulation.
ACC/AHA announce revisions to 2011 Heart Failure Measure set
The American College of Cardiology and the American Heart Association, in collaboration with the Heart Failure Society of America, released retired, revised and new measures for the 2011 Heart Failure Measure set.
EF in low-normal range may increase HF hospitalization risk in Black patients
Low-normal ejection fraction in Black participants was linked to an increased risk for incident HF hospitalization compared with those with normal EF, researchers found.
Dapagliflozin may cut hyperkalemia risk in half for patients with heart failure
Patients with heart failure and reduced ejection fraction who were randomized to dapagliflozin had half the risk of moderate to severe hyperkalemia vs. placebo, according to results of the DAPA-HF trial presented at ASN Kidney Week.
Finerenone effective in reducing cardiac, ESKD risk in patients with diabetes
Data presented at ASN Kidney Week showed the mineralocorticoid receptor inhibitor antagonist finerenone was effective in reducing cardiac risk and slowing the progression of chronic kidney disease in patients with diabetes.